topical treatment of ulcerative colitis using enemas containing 5-aminosalicylic acid and beclomethasone dipropionate
Clicks: 197
ID: 173415
1990
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
197 views
22 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #69 of 250 articles by views in indian journal of pharmacology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 250 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
5-Aminosalicylic acid (5-ASA) enemas constitute a first-line
therapy for patients with mild to moderate attacks of ulcerative colitis. To date,
based on the results of different studies, 5-ASA enemas appear to be satisfactory
in at least two-thirds of patients treated. Beclomethasone is one of the new
corticosteroids which appear to have minimal systemic effects. The authors have
assessed the efficacy of a four week course of 3 mg beclomethasone enemas
compared to 2 g 5-ASA enemas in patients with ulcerative colitis. Preliminary
analysis would suggest that both therapies are effective in more than 50% of cases.
| Reference Key |
campieri1990canadiantopical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;M Campieri;P Gionchetti;A Belluzzi;M Tampieri;C Brignola;M Ferretti;M Miglioli;L Barbara |
| Journal | indian journal of pharmacology |
| Year | 1990 |
| DOI |
10.1155/1990/164896
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.